Joseph Dejoan
Internal Medicine · Hobart, INNPI 1497714364
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $514 and has fallen 61.9% since, to $196 in 2025.
Across 86 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$299
- AbbVie$267
- Exact Sciences$161
- Novo Nordisk$130
- AstraZeneca$127
- GSK$69
- plus $464 from 16 others
What the payments were for
- Food & beverage$1,516100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 20 | $299 |
| AbbVie(2 entities) | 16 | $267 |
| Exact Sciences | 3 | $161 |
| Novo Nordisk | 7 | $130 |
| AstraZeneca | 8 | $127 |
| GSK | 4 | $69 |
| Merck | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Abbott | 2 | $42 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $38 |
| Pfizer | 2 | $36 |
| Novartis | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Corium, LLC | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,516 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 31 | $329 |
| Pantoprazole Sodium | 20 | $266 |
| Amlodipine Besylate | 40 | $265 |
| Losartan Potassium | 26 | $255 |
| Rosuvastatin Calcium | 21 | $193 |
| Metformin Hcl | 24 | $184 |
| Meloxicam | 15 | $107 |
| Atorvastatin Calcium | 29 | $102 |
| Furosemide | 11 | $64 |
| Sertraline Hcl | 12 | $43 |
| Lisinopril | 11 | $42 |
| Allopurinol | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Hobart
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.